Abstract

The efficacy of centrifugal pumps for short-term (0-30 days) ventricular support has been widely reported and favorably compared with pulsatile systems. A small, durable, implantable centrifugal blood pump is being developed for medium-term use (up to 6 months). The pump is based on the Medtronic Hemadyne system that has existed in multiple forms over the past 30 years. The pump is approximately the size of a tennis ball, weighs 240 g, and is comprised of a 2.5 cm plastic impeller driven by a radially coupled brushless DC motor. In vitro hydraulic performance was recorded over a wide range of flow conditions on a mock circulatory loop. The pump generated 7 L/min flow against an afterload of 100 mmHg pressure, with a maximum power draw of 10.4 watts. Pulsatile flow was preserved when placed in conjunction with a simulated left ventricle. In vivo testing was performed in 10 healthy sheep for 10-292 hr. Heparin was used to facilitate cannulation, and no anticoagulation was administered after pump implantation. Blood chemistries reflecting hematologic, pulmonary, renal, and hepatic functions were recorded and demonstrated no adverse effects with normal pump operation. Complications were related to kinking of blood conduits and thrombus formation within the cannulae. These results are encouraging and warrant further studies to prove feasibility of this pump as a medium-term implantable ventricular assist device.